| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| Ab175686-100μg |
100μg |
现货  |
| |
| Ab175686-1mg |
1mg |
现货 |
| |
| Ab175686-5mg |
5mg |
现货 |
| |
| Ab175686-10mg |
10mg |
期货 |
|
| 产品名称 | Trastuzumab emtansine (anti-ERBB2), 受体蛋白酪氨酸激酶 erbB-2 抑制剂 |
|---|---|
| 别名 | ado-trastuzumab emtansine | Kadcyla,PRO-132365 | RG-3502 | 曲妥珠单抗-美坦新偶联物 | ERBB2抗体 | ERBB2单克隆抗体 | ERBB2药靶抗体 |
| 英文别名 | Verb b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog antibody | C erb B2/neu protein antibody | CD340 antibody | CD340 antigen antibody | Cerb B2/neu protein antibody | CerbB2 antibody | Erb b2 receptor tyr |
| 规格或纯度 | 无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥90%(SDS-PAGE&SEC-HPLC), 见COA |
| 宿主种属 | 人(Human) |
| 特异性 | ERBB2 |
| 种属反应性 | 人(Human) |
| 偶联 | SMCC-DM1 |
| 作用类型 | 抑制剂 |
| 作用机制 | 受体蛋白酪氨酸激酶 erbB-2 抑制剂 |
| 克隆类型 | 重组抗体 |
|---|---|
| Format | Whole IgG |
| 亚型 | Human IgG1 |
| 轻链亚型 | kappa |
| SDS-PAGE | 145 kDa |
| 纯化方法 | Protein A purified |
| 物理外观 | Liquid |
| 储存缓冲液 | Supplied as a 0.22μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0 |
| 防腐剂 | No |
| 浓度 | 见COA |
| 储存温度 | -80℃储存,避免反复冻融 |
| 运输条件 | 超低温冰袋运输 |
| 稳定性与储存 | 在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。 |
| CAS编号和信息 | 1018448-65-1 |
| 分子类型 | 抗体偶联药物 |
Trastuzumab emtansine (anti-ERBB2) (Ab175686) - Flow Cytometry
Flow Cytometry analysis of MCF7 cells labelling ERBB2 (red) with Trastuzumab emtansine (anti-ERBB2) (Ab175686) at 1.0 μg/mL for 1 hour at 4°C. Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Trastuzumab emtansine (anti-ERBB2) (Ab175686) - ELISA
Immobilized Recombinant Human ErbB2/HER2 protein (rp169607) at 1.0 μg/mL can bind Trastuzumab emtansine (anti-ERBB2) (Ab175686) with the EC₅₀ of 138.5 ng/mL.
Trastuzumab emtansine (anti-ERBB2) (Ab175686) - SEC
The purity of Trastuzumab emtansine (anti-ERBB2) (Ab175686) is more than 95% verified by HPLC.
Trastuzumab emtansine (anti-ERBB2) (Ab175686) - SEC-MS
The drug-to-antibody ratio (DAR) of the Trastuzumab emtansine (anti-ERBB2) (Ab175686) is 3.3.
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
通过匹配包装上的批号来查找并下载产品的 COA，每批产品都进行了严格的验证，您可放心使用！
| 批号(Lot Number) | 证书类型 | 日期 | 货号 |
|---|---|---|---|
 ZJ25F0521284 |
分析证书 | 25-05-09 | Ab175686 |
| ZJ25F0521283 |
分析证书 | 25-05-09 | Ab175686 |
| ZJ25F0521282 |
分析证书 | 25-05-09 | Ab175686 |
| 1. Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, Blättler WA, Lambert JM, Chari RV, Lutz RJ et al.. (2008) Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.. Cancer Res, 68 (22): (9280-90). [PMID:19010901] |
| 2. Dokter W, Ubink R, van der Lee M, van der Vleuten M, van Achterberg T, Jacobs D, Loosveld E, van den Dobbelsteen D, Egging D, Mattaar E et al.. (2014) Preclinical profile of the HER2-targeting ADC SYD983/SYD985: introduction of a new duocarmycin-based linker-drug platform.. Mol Cancer Ther, 13 (11): (2618-29). [PMID:25189543] |
| 3. Nakada T, Sugihara K, Jikoh T, Abe Y, Agatsuma T. (2019) The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy.. Chem Pharm Bull, 67 (3): (173-185). [PMID:30827997] |
| 4. Banerji U, van Herpen CML, Saura C, Thistlethwaite F, Lord S, Moreno V, Macpherson IR, Boni V, Rolfo C, de Vries EGE et al.. (2019) Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study.. Lancet Oncol, 20 (8): (1124-1135). [PMID:31257177] |
| 5. Xu Z, Guo D, Jiang Z, Tong R, Jiang P, Bai L, Chen L, Zhu Y, Guo C, Shi J et al.. (2019) Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985).. Eur J Med Chem, 183 (111682). [PMID:31563805] |
| 6. Nadal-Serrano M, Morancho B, Escrivá-de-Romaní S, Morales CB, Luque A, Escorihuela M, Espinosa Bravo M, Peg V, Dijcks FA, Dokter WHA et al.. (2020) The Second Generation Antibody-Drug Conjugate SYD985 Overcomes Resistances to T-DM1.. Cancers (Basel), 12 (3): (670). [PMID:32183023] |
首页
400-620-6333
